Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBITDA (2020 - 2022)

Historic EBITDA for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.3 million.

  • Atea Pharmaceuticals' EBITDA fell 12924.91% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$116.6 million, marking a year-over-year decrease of 19088.95%. This contributed to the annual value of -$168.4 million for FY2024, which is 2465.04% down from last year.
  • Per Atea Pharmaceuticals' latest filing, its EBITDA stood at -$34.3 million for Q4 2022, which was down 12924.91% from -$8.9 million recorded in Q3 2022.
  • In the past 5 years, Atea Pharmaceuticals' EBITDA registered a high of $117.1 million during Q4 2021, and its lowest value of -$42.1 million during Q1 2022.
  • Moreover, its 3-year median value for EBITDA was -$10.0 million (2020), whereas its average is $427454.5.
  • Its EBITDA has fluctuated over the past 5 years, first soared by 46730.76% in 2021, then tumbled by 46071.14% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' EBITDA stood at $20.6 million in 2020, then surged by 467.31% to $117.1 million in 2021, then crashed by 129.25% to -$34.3 million in 2022.
  • Its last three reported values are -$34.3 million in Q4 2022, -$8.9 million for Q3 2022, and -$31.3 million during Q2 2022.